# Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma

> **NCT07479628** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 31 (estimated)

## Conditions studied

- Thymic Carcinoma

## Interventions

- **OTHER:** adebrelimab plus chemoradiation

## Key facts

- **NCT ID:** NCT07479628
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07479628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07479628, "Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07479628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*